vs

Side-by-side financial comparison of CVB FINANCIAL CORP (CVBF) and MEDIFAST INC (MED). Click either name above to swap in a different company.

CVB FINANCIAL CORP is the larger business by last-quarter revenue ($133.8M vs $75.1M, roughly 1.8× MEDIFAST INC). On growth, CVB FINANCIAL CORP posted the faster year-over-year revenue change (8.4% vs -36.9%). CVB FINANCIAL CORP produced more free cash flow last quarter ($217.3M vs $-6.6M). Over the past eight quarters, CVB FINANCIAL CORP's revenue compounded faster (2.8% CAGR vs -34.4%).

CVB Financial Corp is a U.S. bank holding company operating Citizens Business Bank, serving mainly California markets. It offers commercial banking, personal banking and wealth management solutions for small to medium enterprises, professional firms and individual consumers, with core services including loans, deposit accounts and asset management.

Medifast, Inc. is an American nutrition and weight loss company based in Baltimore, Maryland. Medifast produces, distributes, and sells weight loss and health-related products through websites, multi-level marketing, telemarketing, and franchised weight loss clinics.

CVBF vs MED — Head-to-Head

Bigger by revenue
CVBF
CVBF
1.8× larger
CVBF
$133.8M
$75.1M
MED
Growing faster (revenue YoY)
CVBF
CVBF
+45.3% gap
CVBF
8.4%
-36.9%
MED
More free cash flow
CVBF
CVBF
$224.0M more FCF
CVBF
$217.3M
$-6.6M
MED
Faster 2-yr revenue CAGR
CVBF
CVBF
Annualised
CVBF
2.8%
-34.4%
MED

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
CVBF
CVBF
MED
MED
Revenue
$133.8M
$75.1M
Net Profit
Gross Margin
69.4%
Operating Margin
55.6%
-10.4%
Net Margin
Revenue YoY
8.4%
-36.9%
Net Profit YoY
EPS (diluted)
$0.41
$-1.64

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CVBF
CVBF
MED
MED
Q4 25
$133.8M
$75.1M
Q3 25
$128.6M
$89.4M
Q2 25
$126.4M
$105.6M
Q1 25
$126.7M
$115.7M
Q4 24
$123.5M
$119.0M
Q3 24
$126.5M
$140.2M
Q2 24
$125.3M
$168.6M
Q1 24
$126.6M
$174.7M
Net Profit
CVBF
CVBF
MED
MED
Q4 25
Q3 25
$52.6M
$-2.3M
Q2 25
$50.6M
$2.5M
Q1 25
$51.1M
$-772.0K
Q4 24
Q3 24
$51.2M
$1.1M
Q2 24
$50.0M
$-8.2M
Q1 24
$48.6M
$8.3M
Gross Margin
CVBF
CVBF
MED
MED
Q4 25
69.4%
Q3 25
69.5%
Q2 25
72.6%
Q1 25
72.8%
Q4 24
74.1%
Q3 24
75.4%
Q2 24
73.2%
Q1 24
72.8%
Operating Margin
CVBF
CVBF
MED
MED
Q4 25
55.6%
-10.4%
Q3 25
53.7%
-4.6%
Q2 25
54.4%
-1.0%
Q1 25
54.9%
-1.1%
Q4 24
55.1%
0.6%
Q3 24
53.5%
1.5%
Q2 24
54.9%
-4.7%
Q1 24
52.8%
4.5%
Net Margin
CVBF
CVBF
MED
MED
Q4 25
Q3 25
40.9%
-2.5%
Q2 25
40.0%
2.3%
Q1 25
40.3%
-0.7%
Q4 24
Q3 24
40.5%
0.8%
Q2 24
39.9%
-4.8%
Q1 24
38.4%
4.8%
EPS (diluted)
CVBF
CVBF
MED
MED
Q4 25
$0.41
$-1.64
Q3 25
$0.38
$-0.21
Q2 25
$0.37
$0.22
Q1 25
$0.36
$-0.07
Q4 24
$0.36
$0.08
Q3 24
$0.37
$0.10
Q2 24
$0.36
$-0.75
Q1 24
$0.35
$0.76

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CVBF
CVBF
MED
MED
Cash + ST InvestmentsLiquidity on hand
$376.4M
$167.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$2.3B
$198.9M
Total Assets
$15.6B
$248.0M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CVBF
CVBF
MED
MED
Q4 25
$376.4M
$167.3M
Q3 25
$783.9M
$173.5M
Q2 25
$738.6M
$162.7M
Q1 25
$529.1M
$164.6M
Q4 24
$204.7M
$162.3M
Q3 24
$453.5M
$170.0M
Q2 24
$844.2M
$163.5M
Q1 24
$949.6M
$156.4M
Stockholders' Equity
CVBF
CVBF
MED
MED
Q4 25
$2.3B
$198.9M
Q3 25
$2.3B
$214.7M
Q2 25
$2.2B
$216.0M
Q1 25
$2.2B
$211.0M
Q4 24
$2.2B
$210.1M
Q3 24
$2.2B
$207.3M
Q2 24
$2.1B
$205.3M
Q1 24
$2.1B
$211.0M
Total Assets
CVBF
CVBF
MED
MED
Q4 25
$15.6B
$248.0M
Q3 25
$15.7B
$268.2M
Q2 25
$15.4B
$269.3M
Q1 25
$15.3B
$280.0M
Q4 24
$15.2B
$284.2M
Q3 24
$15.4B
$291.2M
Q2 24
$16.2B
$293.5M
Q1 24
$16.5B
$302.8M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CVBF
CVBF
MED
MED
Operating Cash FlowLast quarter
$221.4M
$-5.3M
Free Cash FlowOCF − Capex
$217.3M
$-6.6M
FCF MarginFCF / Revenue
162.4%
-8.8%
Capex IntensityCapex / Revenue
3.0%
1.8%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$391.5M
$1.2M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CVBF
CVBF
MED
MED
Q4 25
$221.4M
$-5.3M
Q3 25
$81.5M
$12.1M
Q2 25
$53.1M
$-3.4M
Q1 25
$41.9M
$3.4M
Q4 24
$249.8M
$-4.9M
Q3 24
$71.4M
$9.1M
Q2 24
$26.1M
$13.1M
Q1 24
$77.5M
$7.3M
Free Cash Flow
CVBF
CVBF
MED
MED
Q4 25
$217.3M
$-6.6M
Q3 25
$80.7M
$10.8M
Q2 25
$52.3M
$-4.8M
Q1 25
$41.2M
$1.9M
Q4 24
$244.6M
$-7.2M
Q3 24
$70.2M
$7.7M
Q2 24
$24.4M
$11.1M
Q1 24
$77.3M
$5.4M
FCF Margin
CVBF
CVBF
MED
MED
Q4 25
162.4%
-8.8%
Q3 25
62.8%
12.0%
Q2 25
41.4%
-4.5%
Q1 25
32.5%
1.6%
Q4 24
198.0%
-6.1%
Q3 24
55.5%
5.5%
Q2 24
19.5%
6.6%
Q1 24
61.1%
3.1%
Capex Intensity
CVBF
CVBF
MED
MED
Q4 25
3.0%
1.8%
Q3 25
0.7%
1.5%
Q2 25
0.7%
1.3%
Q1 25
0.5%
1.3%
Q4 24
4.2%
1.9%
Q3 24
1.0%
1.0%
Q2 24
1.4%
1.1%
Q1 24
0.1%
1.1%
Cash Conversion
CVBF
CVBF
MED
MED
Q4 25
Q3 25
1.55×
Q2 25
1.05×
-1.36×
Q1 25
0.82×
Q4 24
Q3 24
1.39×
8.04×
Q2 24
0.52×
Q1 24
1.59×
0.88×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons